U.S. FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

Media coverage

• Title	U.S. FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
  Media name/outlet	FirstWord Pharma
  Country	United States
  Date	10/30/18
  Persons	Ralph A Defronzo

• Title	U.S. FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
  Media name/outlet	Pharmacy Choice
  Country	United States
  Date	10/30/18
  Persons	Ralph A Defronzo